More than 1,000 eye care professionals worldwide have been using the AdaptDx® and AdaptDx Pro™ to test for impaired dark adaptation, the earliest biomarker of age-related macular degeneration. Our customers tell the story of how they’re fighting against preventable blindness by identifying AMD at its earliest stages and closely monitoring its progression.
When I purchased my OCT, I must admit there was a learning curve reading the scans. With the AdaptDx, there is only the Rod Intercept to evaluate, so it was extremely easy to interpret and therefore incorporate into my practice.
The AdaptDx Pro and Theia will change the future of AMD care because they make it easier for eye care professionals to test more patients and diagnose disease at an earlier stage.
The AdaptDx Pro is amazing for two primary reasons. One, the portability of it is phenomenal. The other piece that’s critical is that Theia, the onboard AI tech, provides the instructions for the test, so patients get consistent instructions every time.
By being able to test more patients, we’ll ultimately uncover more macular degeneration. That’s good for patients. And I think we all need to realize that what’s good for our patients winds up being good for our practices.
Screening for macular degeneration is important because as we know, once we lose sight in our macula and once it becomes affected, there’s no getting that back. So being proactive is a lot better than being reactive.
Primary eye care conquered glaucoma because they use technology that enabled them to accurately diagnose and monitor the disease.
My patients recognize our practice as an AMD Center of Excellence with a commitment to preventing blindness through early diagnosis and management. MacuLogix has given our doctors the tool to be leaders in early AMD diagnosis.
Dark adaptation testing has allowed me to provide care earlier for many AMD patients. Science tells that I am helping these patients years before they would have developed, clinically evident disease. Patients appreciate this more proactive approach and are very accepting of it.
The AdaptDx Pro is a tool, that not only to gives you hope for better patient outcomes, which is the most important thing, but also helps you to grow your practice. There’s a huge opportunity because AMD is more prevalent than glaucoma, diabetes, and diabetic retinopathy combined.
The current standard is for us to wait around until we see macular degeneration progressing in someone’s eye. We now know we can identify it earlier, up to 3 years earlier before it ever shows up in their eye. I truly believe dark adaptation testing should be the standard of care.